CLRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cellectar Biosciences Inc (CLRB) is not a good buy for a beginner investor with a long-term strategy at this time. The stock exhibits bearish technical indicators, weak financial performance, and lacks strong positive catalysts. Additionally, there are no significant trading signals or recent influential trades to suggest immediate upside potential.
The stock is showing bearish momentum with MACD negatively expanding, RSI in the neutral zone at 33.131, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock closed below the key pivot level of 3.156, with support at 2.778 and resistance at 3.534. Overall, the technical indicators suggest a downtrend.
Additionally, a Phase 1b dose-finding study for CLR 125 in Triple Negative Breast Cancer has been initiated, with early data expected by mid-2026.
The company reported a FY GAAP EPS of -$8.35, indicating significant challenges in profitability. Cash reserves of $13.2 million are only sufficient to fund operations into Q3 2026, raising concerns about future funding. Research and development expenses have significantly decreased, potentially slowing innovation. Analysts have lowered the price target from $18 to $14.
In Q4 2025, the company reported a net income of -$5.3 million, which improved by 124.81% YoY but remains negative. EPS dropped to -1.29, down -23.21% YoY. Revenue and gross margin remain at 0, showing no growth in core financial metrics.
Roth Capital maintains a Buy rating but has lowered the price target from $18 to $14, citing model adjustments and regulatory updates. This reflects tempered optimism about the stock's future performance.
